Acrivon Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ACRV Nasdaq 2836 www.acrivon.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Acrivon Therapeutics, Inc.

Acrivon Therapeutics Launches Phase 1 Cancer Trial, Advances Oncology Pipeline - Oct 12th, 2024 12:28 pm
Acrivon Therapeutics Announces Initial Patient Dosing in Phase 1 Trial of ACR-2316, a Novel WEE1/PKMYT1 Inhibitor Designed Using AP3 for Superior Single-Agent Activity - Oct 11th, 2024 12:00 pm
Acrivon Therapeutics Reports Positive Endometrial Cancer Data from Ongoing ACR-368 Registrational Intent Phase 2 Study at ESMO, Advancement of ACR-2316 into Clinic Ahead of Timelines, and Progress on its AP3 Interactome for Proprietary Data Analysis - Sep 14th, 2024 7:10 am
Acrivon Therapeutics to Present at the Cantor Global Healthcare Conference - Sep 10th, 2024 12:00 pm
Acrivon Therapeutics to Host Virtual Investor Event to Review Positive Phase 2 Clinical Data of ACR-368 Presented at ESMO and Pipeline Progress, Including Clinical Candidate ACR-2316 - Sep 9th, 2024 11:00 am
We're Hopeful That Acrivon Therapeutics (NASDAQ:ACRV) Will Use Its Cash Wisely - Sep 5th, 2024 12:25 pm
Are Medical Stocks Lagging Acrivon Therapeutics, Inc. (ACRV) This Year? - Aug 15th, 2024 1:40 pm
Acrivon Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights - Aug 13th, 2024 12:00 pm
Is Acrivon Therapeutics, Inc. (ACRV) Stock Outpacing Its Medical Peers This Year? - Jun 21st, 2024 1:40 pm
Is Acrivon Therapeutics, Inc. (ACRV) Outperforming Other Medical Stocks This Year? - Jun 5th, 2024 1:40 pm
Acrivon Therapeutics to Present at the Jefferies Global Healthcare Conference - May 29th, 2024 12:00 pm
Here's Why You Should Buy Acrivon Therapeutics (ACRV) Stock - May 28th, 2024 1:47 pm
5 Small Drug Stocks to Buy From a Recovering Industry - May 24th, 2024 12:59 pm
Has Acrivon Therapeutics, Inc. (ACRV) Outpaced Other Medical Stocks This Year? - May 20th, 2024 1:40 pm
Acrivon Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights - May 14th, 2024 12:00 pm
Is a Surprise Coming for Acrivon Therapeutics (ACRV) This Earnings Season? - May 10th, 2024 12:50 pm
While institutions own 26% of Acrivon Therapeutics, Inc. (NASDAQ:ACRV), private equity firms are its largest shareholders with 50% ownership - May 9th, 2024 10:09 am
Acrivon Therapeutics Reports Initial Positive Clinical Data for ACR-368 and Pipeline Program Progress Today at Corporate R&D Event - Apr 24th, 2024 8:01 pm
Acrivon Therapeutics to Host Corporate R&D Event Highlighting AP3 and Pipeline Progress, Including Ongoing Prospective Validation of ACR-368 OncoSignature with Initial Phase 2 Data for ACR-368, and Preclinical Progress for ACR-2316 - Apr 17th, 2024 12:01 am
Acrivon Therapeutics Presents Data at AACR Annual Meeting Highlighting the Capabilities of Acrivon Predictive Precision Proteomics (AP3) for the Discovery of ACR-2316, a Novel, Selective WEE1/PKMYT1 Inhibitor, and the Identification of Actionable Resistance Mechanisms to ACR-368 - Apr 10th, 2024 12:00 pm